Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Ayad Ahmed Hussein; Constantijn M Halkes; Gérard Socié; André Tichelli; Peter A von dem Borne; Michel N P M Schaap; Robin Foa; Arnold Ganser; Carlo Dufour; Andrea Bacigalupo; Anna Locasciulli; Mahmoud Aljurf; Christina Peters; Marie Robin; Anja A van Biezen; Liisa Volin; Theo De Witte; Judith Marsh; Jakob R Passweg; Nicolas Kröger; Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation

doi:10.1016/j.bbmt.2014.05.028

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Biol Blood Marrow Transplant. 2014 Sep;20(9):1448-50. doi: 10.1016/j.bbmt.2014.05.028. Epub 2014 Jun 6.

Authors

Ayad Ahmed Hussein¹, Constantijn M Halkes², Gérard Socié³, André Tichelli⁴, Peter A von dem Borne², Michel N P M Schaap⁵, Robin Foa⁶, Arnold Ganser⁷, Carlo Dufour⁸, Andrea Bacigalupo⁹, Anna Locasciulli¹⁰, Mahmoud Aljurf¹¹, Christina Peters¹², Marie Robin³, Anja A van Biezen¹³, Liisa Volin¹⁴, Theo De Witte⁵, Judith Marsh¹⁵, Jakob R Passweg¹⁶, Nicolas Kröger¹⁷; Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation

Affiliations

¹ Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
² BMT Centre Leiden, Leiden University Hospital, Leiden, The Netherlands.
³ Department of Hematology-BMT, Hospital St Louis, Paris, France.
⁴ Hematology Division, Basel University Hospital, Basel, Switzerland.
⁵ Department of Hematology and Radboud Institute of Molecular Life Sciences, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands.
⁶ Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy.
⁷ Department of Hematology, Homeostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
⁸ Institute G. Gaslini, Genova, Italy.
⁹ Department of Haematology II, Ospedale San Martino, Genova, Italy.
¹⁰ Haematology and SCT Unit, Ospedale San Camillo, Rome, Italy.
¹¹ Department of Oncology (Section of Adult Hematology/BMT), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
¹² Stem Cell Transplantation Unit, St Anna Kinderspital, Vienna, Austria.
¹³ EBMT Data Office, Department of Medical Statistics and Bioinformatics, LUMC, Leiden, The Netherlands.
¹⁴ Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
¹⁵ Department of Haematological Medicine, GKT School of Medicine, London, United Kingdom.
¹⁶ Hematology Division, Basel University Hospital, Basel, Switzerland. Electronic address: [email protected].
¹⁷ Bone Marrow Transplantation Center, University Hospital Eppendorf, Hamburg, Germany.

PMID: 24910382
DOI: 10.1016/j.bbmt.2014.05.028

Abstract

One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

Keywords: Acute myelogenous leukemia; Hematopoietic stem cell transplantation; Myelodysplastic syndrome; Severe aplastic anemia.

MeSH terms

Adolescent
Adult
Aged
Anemia, Aplastic / therapy*
Child
Child, Preschool
Europe
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Infant
Leukemia
Male
Middle Aged
Myelodysplastic Syndromes
Neoplasm Recurrence, Local
Transplantation Conditioning / adverse effects*
Transplantation, Homologous / adverse effects*
Treatment Outcome
Young Adult